Reading the tape
NASDAQ: CRVS
Corvus Pharmaceuticals, Inc.
Healthcare · Biotechnology
Market Cap
$1.31B
52w High
$26.95
52w Low
$3.17
P/E
-80.58
Volume
29.95K
Outstanding Shares
84.09M
Price vs Fundamentals
Why The Stock Is Moving
Mixed / unclearLow confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: 330.05%FCF (TTM): -29.68%
What changed
The stock rose 330.05% over the last year. Free cash flow declined 29.68% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
A decisive shift in revenue or cash flow over the next period would be the clearest signal to resolve the ambiguity.
Company profile
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies.
CEORichard A. Miller
SectorHealthcare
IndustryBiotechnology
Employees31
IPO dateMar 23, 2016
Valuation
Forward P/E—
EV/EBITDA-14.07
Enterprise value$604.39M
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Revenue growth—
Gross margin0%
Operating margin0%
ROE-24.97%▲86.95%vs FY2024
Analyst consensus
RatingBuy
Target price$33.17▲112.70%
12
Buy
1
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 7, 2026
Q2 FY26 · EPS est -$0.14 · Revenue est —
View